ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On October 15, 2020, Adaptimmune Therapeutics plc issued a press release providing full contents of its Society for the Immunotherapy of Cancer (SITC) Abstract for its Phase 1 SURPASS Trial. The press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

 (d)  Exhibits.



      Exhibit No.                        Description of Exhibit

        99.1           Press release dated October 15, 2020

      104            Cover Page Interactive Date File (embedded within the Inline
                     XBRL document)

© Edgar Online, source Glimpses